Get your non-viral T cell engineering process ready for clinical manufacturing

Cell & Gene Therapy Insights 2024; 10(5), 671

DOI: 10.18609/cgti.2024.080

Published: 5 June
Melanie Rietenbach

Watch the video or view the poster to learn about:

  • How to close and automate your T cell electroporation protocol to get it ready for clinical manufacturing      
  • How complex gene modifications are enabled by the combination of electroporation and transduction
  • How to tackle challenges during process development and translation into clinical manufacturing

Melanie Rietenbach is a Global Product Manager and Group Leader for the Immunotherapy portfolio at Miltenyi Biotec. During the last 4 years, she has been working together with the R&D and Clinical Development Team in order to advance the development of tools to enable engineered T cell immunotherapy. Before that, Melanie already supported Miltenyi Biotec in her role as Application Development Specialist and Clinical Product Specialist for more than 3 years. During that time, she was responsible for technical support and application training on Miltenyi Biotec’s clinical product portfolio with focus on cell and gene therapy applications and related products.